Love them or hate them, copay accumulator programs probably aren't going away anytime soon. We'll have to see how the market evolves over time with manufacturers and payers adapting these programs to counteract each other. The dance continues!
The pharmaceutical industry remained in the headlines last year, although not always for the best reasons. Precision's Andrew Cournoyer, RPh, and Dan Danielson, RPh, MS, give us their takes on the various pharma happenings in 2019.
What are the biggest key takeaways from 2019? In the latest All Access newsletter by Precision for Value we asked our advisors to reflect on the market events for the year by type of payer.
The FDA has finally released its guidance on biosimilar interchangeability. Radar on Specialty Pharmacy speaks with Ryan Cox, Precision for Value Vice President, Access Experience team on how the new guidelines reduce administrative hurdles and duplicative clinical trials. However, he notes that reimbursement issues may discourage uptake.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
